Savana is the creator of
AI-generated clinical
evidence since 2014.

Savana is the creator of
AI-generated clinical
evidence since 2014.

Savana is the creator of
AI-generated clinical
evidence since 2014.

Top 10 HEOR solutions providers in Europe 2023.

“THE ANNUAL LISTING OF 10 COMPANIES IN EUROPE THAT ARE THE FOREFRONT OF PROVIDING HEOR SOLUTIONS”

The AI + RWE Company for:

Healthcare

Providers:

Reuse Electronic Medical Records thanks to Natural Language Processing and transform them into actionable knowledge.

Life Sciences

Companies:

Collaborate in the creation of disease RWE allowing data to be easily reachable allowing best patient care in real time.

Healthcare

Providers:

Reuse Electronic Medical Records thanks to Natural Language Processing and transform them into actionable knowledge.

Life Sciences

Companies:

Collaborate in the creation of deep RWE allowing data to be easily reachable allowing best patient care in real time.

Clinical Natural Language Processing.

MACHINE LEARNING APPLIED TO MEDICAL RECORDS

Multi-language:

  • Anonymization.
  • Section Detection.
  • NER (Named Entity Recognition).
  • Negation/Speculation.
  • Temporality.
  • NED (Named Entity Disambiguation).
  • Acronym NED.

150 1345 14568 235678 5678421 2 billion 4 billion 5 billion clinical acts analyzed applying top AI techniques and own AI models.

Savana data modelling is set up following the OMOP Common Data Model.

Complying to OHDSI standards to enable efficient analysis and reliable evidence.

Savana is ISO 27001 certified, the global standard for information security management.

2023 European Patent:
Patient Privacy mathematical formula.

Publications.

PEER-REVIEWED SCIENTIFIC JOURNALS PUBLICATIONS

Reality Checks.

WE TESTED OUR CAPABILITIES THROUGH REALITY CHECKS

Real-world evidence analysis of early-stage prostate cancer using natural language processing.

WHAT

A Real-World Evidence analysis of early-stage prostate cancer using natural language processing.

WHY THIS WORK IS REMARKABLE

Because in an area (early-stage prostate cancer) where RWE is lacking, 365 variables from almost 20.000 patients in 12 hospitals could be analyzed.

WHAT WAS THE CONSEQUENCE

There is now RWE in early-stage prostate cancer, including clinical characteristics, treatment patterns and journey across different prostate cancer stages; event-free survival could be analyzed in incident LPC patients with presence of Gleason or PSA and follow-up greater than 0 days.

WHAT THIS WORK DEMONSTRATES

The RWE generated through NLP applied to Electronic Medical Records is robust and valid, also in the area of cancer, providing high numbers of patients with a fraction of the human effort.

Real-world evidence analysis of early-stage prostate cancer using natural language processing.

WHAT

A Real-World Evidence analysis of early-stage prostate cancer using natural language processing.

WHY THIS WORK IS REMARKABLE

Because in an area (early-stage prostate cancer) where RWE is lacking, 365 variables from almost 20.000 patients in 12 hospitals could be analyzed.

WHAT WAS THE CONSEQUENCE

There is now RWE in early-stage prostate cancer, including clinical characteristics, treatment patterns and journey across different prostate cancer stages; event-free survival could be analyzed in incident LPC patients with presence of Gleason or PSA.

WHAT THIS WORK DEMONSTRATES

The RWE generated through NLP applied to Electronic Medical Records is robust and valid, also in the area of cancer, providing high numbers of patients with a fraction of the human effort.

Savana is a member of the
Forbes' "2023 Changemakers" List.

Savana’s clinical research.

GENERATING MULTIREGIONAL AND MULTILINGUAL RWE

9

Years experience in AI.

5 Billion

Clinical documents processed.

32

Different EMR systems handled.

36

Diseases in which we worked.

+100.000

AI-generated variables.

231

Researchers that investigated in our studies.

+20 Mill.

Unique patients

13

Countries.

5

Languages.

+250

Sites that participated in studies.

Top 25

Pharma RWE companies.

AI + RWE Studies.

RWE STUDIES ACROSS 17 THERAPEUTIC AREAS AND 13 COUNTRIES

Cardiology

  • Atrial Fibrillation
  • Coronary disease and Diabetes Mellitus type II

Dermatology

Endocrinology

  • Diabetes Mellitus Type I & II
  • Hyperparathyroidism

Gastroenterology

Hematology

  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Amyloidosis
  • Hemophilia B

ICU

  • Sepsis

Immunology

  • Primary & Secondary Immunodeficiencies

Neurology

  • Ischemic Stroke
  • Motor Neuron Disease/Amyotrophic lateral sclerosis
  • Multiple Sclerosis
  • Post-stroke spasticity with Botulinum Toxin

Obstetrics

  • Postpartum Bleeding

Ophthalmology

  • Conjunctivitis

Traumatology & Orthopedics

  • Hip Fractures
  • Second Hip Fractures
  • Carpal Tunnel

Discover how Savana applies Natural Language Processing
and Machine Learning to clinical data:

Savana is supported by European Union funds.

01. European Union 

Next Generation funds:

02. European Regional

Development funds:

(DeID Station Project)

Complete the info, and a KAM will contact you ASAP:

Want to use it?:

Start with your proposed AI + RWE use case:

This is the first step for AI + RWE: